-
Stephan Moll, MD writes (last updated: Sept 9th, 2020)… Background: Hospitalized patients with COVID-19 are at increased risk for thrombosis – DVT, PE, and may be pulmonary micro-vascular thrombosis that possibly contributes to respiratory failure; arterial events appear to occur less commonly. Scientific/clinical data on prevalence of thrombosis, best prevention, and optimal therapy are limited.
-
Stephan Moll, MD writes… On Oct 8th, 2013 the FDA approved Adempas® (riociguat), a new oral drug to treat pulmonary hypertension. The drug is a guanylate cyclase stimulator that leads to arteries dilatation. It is intended for: Patients with chronic thromboembolic pulmonary hypertension (CTEPH)
-
Stephan Moll, MD writes… Interesting publication this week in Circulation: “Management and outcomes of major bleeding during treatment with dabigatran or warfarin” (Majeed A et al; published online Sept 30,2013; full publication is here). The management and prognosis of major bleeding in patients treated with dabigatran or warfarin was compared, pooling data of the major bleeds that occurred in 5 phase III
-
Stephan Moll, MD writes… Today, Sept 1st, 2013, the New England Journal of Medicine published the phase 3 clinical trial of edoxaban versus warfarin in the treatment of DVT and PE [ref 1]. It showed that edoxaban was as effective as warfarin and led to less clinically relevant bleeding.
-
Stephan Moll, MD writes… 1. Pradaxa (Dabigatran) Today, August 28th, 2013, it was announced that the FDA is reviewing the application by Boehringer-Ingelheim to get Pradaxa (dabigatran) approved for use in patients with deep vein thrombosis (DVT) and pulmonary embolism (PE) – details here. At present, in the US, Pradaxa is only FDA-approved for
-
Stephan Moll, MD writes… A major international coagulation conference, the bi-annual meeting of the International Society for Thrombosis and Haemostasis (ISTH; http://www.isth.org), took place in Amsterdam, Holland, from June 29th to July 4th, 2013. The clinically relevant highlights about thrombosis and anticoagulation are summarized below.
-
Stephan Moll, MD writes… An important study (AMPLIFY trial) was published today in the New England Journal of Medicine [ref 1]: In a large study of 5395 patients with acute DVT or PE, Eliquis (apixaban) was as effective as warfarin and caused less major bleeding.
-
Dr. Stephan Moll writes… Skyla® is a new IUD (intrauterine device) contraceptive, approved in February 2013 by the FDA. Skyla® is like a small version of the Mirena® IUD. It has the following features:
-
Stephan Moll, MD writes…. Recurrent DVT can be challenging to diagnose, as it may be difficult on Doppler ultrasound to tell chronic changes from additional new clot. A guidance statement from the ISTH (International Society for Thrombosis and Haemostasis) published this week (May 18th, 2013) provides solid, clinically useful, evidence-based recommendations
-
Stephan Moll, MD writes…. Freshly published just now (May 2013), the 3rd edition of the very clinical-practical Consultative Hemostasis and Thrombosis textbook edited by Kitchens, Kessler & Konkle – link here. 822 pages, 47 chapters on bleeding and clotting disorders, diagnosis, management. Suitable for whom? Useful as a reference for all practicing physicians and midlevel providers who
-
Stephan Moll, MD writes…. The pharmaceutical company Portola reported today (May 8th, 2013) without many details on the findings of their phase 2 human volunteer study of their anti-Xa anticoagulant antidote PRT4445 — ClinicalTrials.gov Identifier: NCT01758432 (study description here). In this study, healthy volunteers who had taken Eliquis (Apixaban) received the antidote. The study showed a “rapid and sustained and dose-related reversal of the
A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center
Clot Connect 